SARS-CoV-2-IN-13
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally.
Product Specifications
CAS Number
56961-10-5
Field of Research
Infectious Disease & Virology
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : ≥ 125 mg/mL (382.12 mM)
Smiles
Oc1ccc (Cl) cc1C (=O) Nc1ccc (c (Cl) c1) [N+] ([O-]) =O
Molecular Formula
C13H8Cl2N2O4
Molecular Weight
327.12
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS013046-03 5x 96 Well
Hamster Matrix Metalloproteinase 28 ELISA Kit
Sign In for Pricing
View Details MBS013046-04 10x 96 Well
Hamster Matrix Metalloproteinase 28 ELISA Kit
Sign In for Pricing
View Details 
MBS6435283-01 0.1 mL
RCL1 (RNA 3'-terminal Phosphate Cyclase-like Protein, RNAC, RPCL1) (MaxLight 750)
Sign In for Pricing
View Details MBS6435283-02 5x 0.1 mL
RCL1 (RNA 3'-terminal Phosphate Cyclase-like Protein, RNAC, RPCL1) (MaxLight 750)
Sign In for Pricing
View Details